Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer

Moayad Alhumaid; Salma Sait; Emad Fallatah; Nasser AlSayegh; Ali Farsi; Mohammed Nassif; Nada J Farsi; Nouf Akeel; Ali Samkari; Alaa A Shabkah; Nora Trabulsi

doi:10.7759/cureus.18670

Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer

Cureus. 2021 Oct 11;13(10):e18670. doi: 10.7759/cureus.18670. eCollection 2021 Oct.

Authors

Affiliations

¹ Department of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
² Department of Dental Public Health, King Abdulaziz University Faculty of Dentistry, Jeddah, SAU.
³ Department of Surgery, International Medical Center, Jeddah, SAU.

Abstract

Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were included in the final assessment. Pooled three- and five-year OS rates were 58.60% and 42.19%, respectively. The estimated pooled three- and five-year DFS rates were 23.47% and 14.26%, respectively.

Keywords: colorectal neoplasm; cytoreductive surgery (crs); cytoreductive surgery and hipec; oxaliplatin; peritoneal carcinoma; systematic review and meta-analysis.

Publication types

Review